Table 1

Effect of various in vitro treatments on the concentration-response curves to des-Arg9-BK in 5-h-incubated HUV

TreatmentPeriodpEC50Maximal response (g)n
ControlTreatedControlTreated
Bay 11-7082 (3 μM)0–5 h7.57 ± 0.137.31 ± 0.0611.1 ± 1.59.4 ± 0.44
Bay 11-7082 (10 μM)0–5 h7.32 ± 0.046.93 ± 0.0616.6 ± 1.312.0 ± 1.71-150 6
Bay 11-7082 (30 μM)0–5 h7.53 ± 0.19Not determined11.6 ± 2.00.3 ± 0.31-150 3
Bay 11-7082 (10 μM)4.5–5 h7.32 ± 0.047.25 ± 0.0516.6 ± 1.314.8 ± 0.86
MG-132 (0.3 μM)0–5 h7.61 ± 0.077.53 ± 0.0612.5 ± 1.611.2 ± 1.64
MG-132 (1 μM)0–5 h7.37 ± 0.147.00 ± 0.1114.6 ± 2.08.5 ± 2.71-150 7
MG-132 (10 μM)0–5 h7.70 ± 0.13Not determined19.1 ± 2.47.0 ± 2.51-150 3
MG-132 (1 μM)4.5–5 h7.42 ± 0.107.49 ± 0.0914.8 ± 1.915.6 ± 2.57
Interleukin-6 (10 ng/ml)0–3 h7.66 ± 0.077.93 ± 0.061-150 16.9 ± 2.215.7 ± 1.66
Interleukin-4 (20 ng/ml)0–5 h7.72 ± 0.087.29 ± 0.121-150 14.0 ± 1.511.8 ± 1.55
Interleukin-4 (20 ng/ml)4.5–5 h7.26 ± 0.127.50 ± 0.1311.3 ± 1.012.0 ± 1.34
TGF-β1 (3 ng/ml)0–5 h7.64 ± 0.047.23 ± 0.041-150 15.0 ± 1.412.7 ± 1.06
TGF-β1 (3 ng/ml)4.5–5 h7.68 ± 0.087.56 ± 0.1115.3 ± 3.214.0 ± 2.85
  • 1-150  Significant differences between treated and paired control tissues (P < 0.05).